STAT3 and cancer: Very recent data, however, reported a positive outcome from the use of silibilin, a molecule that impairs STAT3 activation via direct interaction with STAT3 [22], in cancer patients with brain metastases expressing high levels of STAT3 activation in reactive astrocytes surrounding the cerebral lesion [13].